15th Jan 2019 11:18
LONDON (Alliance News) - MaxCyte Inc on Tuesday guided for a 19% increase in its 2018 revenue with the firm expecting its annual earnings to exceed market views.
The life science company said revenue in 2018 will come in at approximately USD16.7 million, up from USD14.0 million a year ago, with revenue in the second half amounting to USD9.7 million versus USD7.8 million a year ago.
Earnings before interest, taxes, depreciation and amortisation are expected to be "an improvement on market expectations", MaxCyte added.
"The company remains focused on advancing the high value CARMA programme where the board believes there is a very significant opportunity for MaxCyte, and continuing to expand its operations across the fast-growing bioprocessing and cell therapy markets. MaxCyte's board anticipates continued strong growth for the current 2019 financial year," the firm added.
MaxCyte shares were untraded at 185.00 pence each.
Related Shares:
MaxCyte